Rethinking Uncertainty in Segmentation: From Estimation to Decision
arXiv cs.AI / 4/16/2026
💬 OpinionIdeas & Deep AnalysisModels & Research
Key Points
- The paper argues that medical segmentation pipelines typically estimate uncertainty but do not use it to drive downstream actions like accepting, flagging, or deferring predictions.
- It reframes segmentation as a two-stage process—uncertainty estimation followed by decision-making—and shows that optimizing uncertainty metrics alone misses much of the potential safety improvement.
- Experiments on retinal vessel segmentation benchmarks (DRIVE, STARE, CHASE_DB1) compare uncertainty sources including Monte Carlo Dropout and Test-Time Augmentation, paired with multiple deferral strategies.
- The authors propose a confidence-aware deferral rule and report that the best method-policy combination can remove up to 80% of segmentation errors while deferring only about 25% of pixels, with strong cross-dataset robustness.
- A key finding is that improvements in calibration do not necessarily improve decision quality, indicating a disconnect between common uncertainty measures and real-world utility.
Related Articles
"The AI Agent's Guide to Sustainable Income: From Zero to Profitability"
Dev.to
"The Hidden Economics of AI Agents: Survival Strategies in Competitive Markets"
Dev.to
Big Tech firms are accelerating AI investments and integration, while regulators and companies focus on safety and responsible adoption.
Dev.to
"The Hidden Costs of AI Agent Deployment: A CFO's Guide to True ROI in Enterpris
Dev.to
"The Real Cost of AI Compute: Why Token Efficiency Separates Viable Agents from
Dev.to